Accelerating HIV vaccine development using non-human primate models
Introduction: The search for a preventative HIV vaccine is ongoing after three decades of research. Contributions of non-human primate (NHP) models to this research are irrefutable, however interpreting data obtained for translation to humans has been problematic. As knowledge concerning NHP models...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-01-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/14760584.2019.1557521 |
| _version_ | 1797680359106674688 |
|---|---|
| author | Mohammad Arif Rahman Marjorie Robert-Guroff |
| author_facet | Mohammad Arif Rahman Marjorie Robert-Guroff |
| author_sort | Mohammad Arif Rahman |
| collection | DOAJ |
| description | Introduction: The search for a preventative HIV vaccine is ongoing after three decades of research. Contributions of non-human primate (NHP) models to this research are irrefutable, however interpreting data obtained for translation to humans has been problematic. As knowledge concerning NHP models has accumulated, their utility and value in assessing immunogenicity and efficacy of novel vaccines have become apparent. NHP models have become a critical component of vaccine design. Areas covered: Beginning with early vaccine studies, we trace the development and evolution of NHP models concurrent with changes in HIV vaccine concepts and in response to their ability to predict clinical trial efficacy. The value of NHP studies in guiding vaccine design is highlighted along with their importance in opening new areas of investigation and facilitating movement of promising approaches into the clinic. Expert commentary: Due to their close relatedness to humans, NHPs are an excellent choice for immunogenicity studies. The ability of NHP models to predict clinical efficacy has improved with the introduction of low-dose challenge viruses and recognition of confounding variables in study outcomes. Use of NHP models has opened new research areas with outstanding potential for generating vaccine efficacy against HIV and other infectious agents. |
| first_indexed | 2024-03-11T23:28:51Z |
| format | Article |
| id | doaj.art-605cf95d07184f5d9c03cf3ee14d1f58 |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-03-11T23:28:51Z |
| publishDate | 2019-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-605cf95d07184f5d9c03cf3ee14d1f582023-09-20T10:18:04ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952019-01-01181617310.1080/14760584.2019.15575211557521Accelerating HIV vaccine development using non-human primate modelsMohammad Arif Rahman0Marjorie Robert-Guroff1National Cancer Institute, National Institutes of HealthNational Cancer Institute, National Institutes of HealthIntroduction: The search for a preventative HIV vaccine is ongoing after three decades of research. Contributions of non-human primate (NHP) models to this research are irrefutable, however interpreting data obtained for translation to humans has been problematic. As knowledge concerning NHP models has accumulated, their utility and value in assessing immunogenicity and efficacy of novel vaccines have become apparent. NHP models have become a critical component of vaccine design. Areas covered: Beginning with early vaccine studies, we trace the development and evolution of NHP models concurrent with changes in HIV vaccine concepts and in response to their ability to predict clinical trial efficacy. The value of NHP studies in guiding vaccine design is highlighted along with their importance in opening new areas of investigation and facilitating movement of promising approaches into the clinic. Expert commentary: Due to their close relatedness to humans, NHPs are an excellent choice for immunogenicity studies. The ability of NHP models to predict clinical efficacy has improved with the introduction of low-dose challenge viruses and recognition of confounding variables in study outcomes. Use of NHP models has opened new research areas with outstanding potential for generating vaccine efficacy against HIV and other infectious agents.http://dx.doi.org/10.1080/14760584.2019.1557521non-human primatevaccinehumoral, cellular, and innate immunityhivsivshivclinical trials |
| spellingShingle | Mohammad Arif Rahman Marjorie Robert-Guroff Accelerating HIV vaccine development using non-human primate models Expert Review of Vaccines non-human primate vaccine humoral, cellular, and innate immunity hiv siv shiv clinical trials |
| title | Accelerating HIV vaccine development using non-human primate models |
| title_full | Accelerating HIV vaccine development using non-human primate models |
| title_fullStr | Accelerating HIV vaccine development using non-human primate models |
| title_full_unstemmed | Accelerating HIV vaccine development using non-human primate models |
| title_short | Accelerating HIV vaccine development using non-human primate models |
| title_sort | accelerating hiv vaccine development using non human primate models |
| topic | non-human primate vaccine humoral, cellular, and innate immunity hiv siv shiv clinical trials |
| url | http://dx.doi.org/10.1080/14760584.2019.1557521 |
| work_keys_str_mv | AT mohammadarifrahman acceleratinghivvaccinedevelopmentusingnonhumanprimatemodels AT marjorierobertguroff acceleratinghivvaccinedevelopmentusingnonhumanprimatemodels |